摘要:
A non-linear optical device is provided in which an organic compound is disposed in a light beam. The organic compound is a benzalacetofuran derivative represented by the following formula (I) ##STR1## wherein R is CH.sub.3, CH.sub.3 S, Br, CN or NO.sub.2.
摘要:
A non-linear optical material comprises a derivative of chalcone represented by the following general formulae (I) or (II) of: ##STR1## wherein R.sub.1 and R.sub.2 each represent a halogen atom, a hydroxyl group, an amino group, a dimethylamino group, a nitro group, a cyano group, a phenyl group, an acetyl group, an alkyl group having 1 to 18 carbon atoms or an alkyloxy group having 1 to 22 carbon atoms; n.sub.1 and n.sub.2 each represent an interger of from 0 to 21; and m.sub.1 and m.sub.2 each represent an integer of from 0 to 5.
摘要:
A non-linear optical material consists essentially of 3-(2-thienyl)-1-(4-methylphenyl)propene-3-one represented by the formula (I) ##STR1## A non-linear optical device contains an organic compound disposed in a light beam. The organic compound is represented by the formula (I) and has a crystal in which a space group determined by the X-ray analytical method is P2.sub.1.
摘要:
A non-linear optical article is constituted of a derivative of benzalacetophenone represented by the following general formula: ##STR1## wherein A and B each represent the same or different atom or group and stand for a hydrogen atom, an alkoxy group having 1 to 4 carbon atoms, a chlorine atom, a bromine atom, an amino group or a dialkylamino group having 1 to 2 carbon atoms.
摘要:
A method for quantification of a titer of a neutralizing antibody to a neurotoxin is disclosed. The method comprises the steps: (a) mixing a standard sample containing a fixed amount of a neurotoxin and a test sample containing a neutralizing antibody to said neurotoxin; (b) administering the mixture obtained in step (a) into the muscle of a non-human mammal; (c) applying electric stimulus to said non-human mammal; (d) measuring a compound muscle action potential (CMAP) due to contraction of the muscle of said mammal by application of electric stimulus with an electromyograph; and (e) analyzing CMAP amplitude data obtained in step (d) for an extent of decrease in amplitude by a non-neutralized neurotoxin to thereby quantify a titer of the neutralizing antibody contained in the test sample.
摘要:
A pharmaceutical preparation for use in a patient who has a neutralizing antibody to a botulinum toxin from type A1 Clostridium botulinum (type A1 botulinum toxin), said preparation comprising as an active ingredient 150 kDa type A neurotoxin from type A2 Clostridium botulinum (A2 NTX); a medicament for treating a disease with muscle overactivity for use in a patient who has a neutralizing antibody to a type A1 botulinum toxin, said medicament comprising as an active ingredient said A2 NTX; a method for treating a patient who has a neutralizing antibody to a type A1 botulinum toxin, said method comprising administering said A2 NTX to the patient; and a method for use of A2 NTX in a patient who has said neutralizing antibody. In accordance with the present invention, a problem can be solved of decrease in clinical response caused by a neutralizing antibody to a type A1 botulinum toxin produced when a patient is treated with a pharmaceutical preparation comprising a type A1 botulinum toxin.
摘要:
A novel type A botulinum toxin preparation is provided. A neuromuscular transmission blocking agent comprising as an active ingredient a highly purified type A botulinum toxin from Clostridium botulinum as infant botulism pathogen and a medicament for treating a disease with a muscle overactivity comprising as an active ingredient said toxin. In particular, the medicament of the present invention, as compared to the conventional known botulinum toxin preparations, has rapid efficacy of potential and is less diffusive and thus, having a broader safety margin, may be used as therapeutic medicament for decreasing local, muscle overactivity in a disease with a muscle overactivity.
摘要:
Fluorine-containing polyfunctional (meth)acrylate represented by the formula (1), a monomer composition containing the (meth)acrylate, a low refractivity material prepared by curing the monomer composition, and a reflection reducing film provided with the low refractivity material. wherein R1, R2, R3, and R4 are the same or different groups, and each stands for a hydrogen atom, an acryloyl group, or a methacryloyl group, at least one of R1 and R2 and at least one of R3 and R4 stand for an acryloyl group or a methacryloyl group, R stands for a fluoroalkylene group having 2 to 12 carbon atoms and 2 or more fluorine atoms.
摘要:
Fluorine-containing polyfunctional (meth)acrylate represented by the formula (1), as well as a composition, a low refractivity material and a reflection reducing film in which the (meth)acrylate is utilized: ##STR1## wherein X stands for a fluoroalkyl group of C1-14 having 3 or more F, or a fluorocycloalkyl group of C3-14 having 4 or more F; Y.sup.1, Y.sup.2, and Y.sup.3 stand for H, an acryloyl group or a methacryloyl group, and at least two of Y.sup.1, Y.sup.2, and Y.sup.3 stand for an acryloyl group or a methacryloyl group; Z stands for H or an alkyl group of C1-3; and n and m is an integer of 0 or 1, and n+m=1.
摘要:
A method for treating a patient who has a neutralizing antibody to a type A1 botulinum toxin. The method includes administering 150 kDa type A neurotoxin from type A2 Clostridium botulinum (A2 NTX) to the patient. In accordance with the present invention, a problem can be solved of decrease in clinical response caused by a neutralizing antibody to a type A1 botulinum toxin produced when a patient is treated with a pharmaceutical preparation containing a type A1 botulinum toxin.